A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)

被引：22

作者：

Yokoyama, Toshihide ^{[1
]}

Yoshioka, Hiroshige ^{[1
,10
]}

Fujimoto, Daichi ^{[2
]}

Demura, Yoshiki ^{[3
]}

Hirano, Katsuya ^{[4
]}

Kawai, Takahiro ^{[5
]}

Kagami, Ryogo ^{[6
]}

Washio, Yasuyoshi ^{[1
]}

Ishida, Tadashi ^{[1
]}

Kogo, Mariko ^{[2
]}

Tomii, Keisuke ^{[2
]}

Okuno, Takehiro ^{[3
]}

Akai, Masaya ^{[3
]}

Hirabayashi, Masataka ^{[4
]}

Nishimura, Takashi ^{[5
]}

Nakahara, Yasuharu ^{[6
]}

Kim, Young Hak ^{[7
]}

Miyakoshi, Chisato ^{[8
]}

Yoshimura, Kenichi ^{[9
]}

Hirai, Toyohiro ^{[7
]}

机构：

[1] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[2] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan

[3] Japanese Red Cross Fukui Hosp, Dept Resp Med, Fukui, Japan

[4] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Hyogo, Japan

[5] Kyoto Katsura Hosp, Dept Resp Med, Kyoto, Japan

[6] Himeji Med Ctr, Dept Resp Med, Himeji, Hyogo, Japan

[7] Kyoto Univ Hosp, Dept Resp Med, Kyoto, Japan

[8] Kobe City Med Ctr Gen Hosp, Clin Res Ctr, Kobe, Hyogo, Japan

[9] Kanazawa Univ, Innovat Clin Res Ctr, Kanazawa, Ishikawa, Japan

[10] Kansai Med Univ Hosp, Dept Thorac Oncol, 2-3-1 Shin Machi, Hirakata, Osaka 5731191, Japan

来源：

LUNG CANCER | 2019年 / 135卷

关键词：

Low starting dose; Afatinib; Epidermal growth factor receptor mutation; Non-small-cell lung cancer; SURVIVAL-DATA; GEFITINIB; ADENOCARCINOMA; CHEMOTHERAPY; INHIBITOR; EFFICACY; IMPACT;

D O I：

10.1016/j.lungcan.2019.03.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Afatinib is an effective treatment in patients who have epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), but its toxicities often require dose adjustment. Exploratory analyses of previous trials have suggested that reducing the dose of afatinib can decrease treatment related adverse events without negatively affecting effectiveness. The aim of this study was to assess the efficacy and safety of low starting dose of afatinib with dose modification according to its toxicity in patients with EGFR mutation-positive NSCLC. Materials and methods: This study was a multicenter, single-arm, open-label phase II trial. Treatment-naive patients with advanced NSCLC positive for common EGFR mutations received afatinib starting in a dose of 20 mg/day. If tolerated, the dose was increased in 10-mg increments up to 50 mg/day. The primary endpoint was progression-free survival (PFS). Results: From February 2015 through March 2016, 46 patients were enrolled. The median age was 73 years (range, 43-86), and 35 patients (72%) were women. EGFR mutation subtypes included exon 19 deletion (54%) and Leu858Arg point mutation (46%). Most patients had a performance status of 0 or 1 (91%) and a histological diagnosis of adenocarcinoma (98%). As of the data cut-off date of June 2017, the median follow-up was 18.9 months. The median PFS was 15.2 months (95% CI: 13.2-not estimable). The 1-year overall survival rate was 95.6% (95% CI: 89.7%-100%). The objective response rate was 81.8% (95% CI, 81.3%-98.6%). Adverse events of grade 3 or higher occurred in 14 patients (30.4%) and included rash/acne in 4 patients (8.7%), paronychia in 4 patients (8.7%), diarrhea in 2 patients (4.3%). There was no treatment-related death. Conclusions: Low starting dose of afatinib therapy showed promising clinical efficacy and good tolerability. Further investigations are warranted.

引用

页码：175 / 180

页数：6

共 15 条

[1] Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations [J].

Ichihara, Eiki ;

Hotta, Katsuyuki ;

Takigawa, Nagio ;

Kudo, Kenichiro ;

Kato, Yuka ;

Hondaa, Yoshihiro ;

Hayakawa, Hiromi ;

Minami, Daisuke ;

Sato, Akiko ;

Tabata, Masahiro ;

Tanimoto, Mitsune ;

Kiura, Katsuyuki .

LUNG CANCER, 2013, 81 (03) :435-439

[2] Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 [J].

Kato, Terufumi ;

Yoshioka, Hiroshige ;

Okamoto, Isamu ;

Yokoyama, Akira ;

Hida, Toyoaki ;

Seto, Takashi ;

Kiura, Katsuyuki ;

Massey, Dan ;

Seki, Yoko ;

Yamamoto, Nobuyuki .

CANCER SCIENCE, 2015, 106 (09) :1202-1211

[3] Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs [J].

Kris, Mark G. ;

Johnson, Bruce E. ;

Berry, Lynne D. ;

Kwiatkowski, David J. ;

Iafrate, A. John ;

Wistuba, Ignacio I. ;

Varella-Garcia, Marileila ;

Franklin, Wilbur A. ;

Aronson, Samuel L. ;

Su, Pei-Fang ;

Shyr, Yu ;

Camidge, D. Ross ;

Sequist, Lecia V. ;

Glisson, Bonnie S. ;

Khuri, Fadlo R. ;

Garon, Edward B. ;

Pao, William ;

Rudin, Charles ;

Schiller, Joan ;

Haura, Eric B. ;

Socinski, Mark ;

Shirai, Keisuke ;

Chen, Heidi ;

Giaccone, Giuseppe ;

Ladanyi, Marc ;

Kugler, Kelly ;

Minna, John D. ;

Bunn, Paul A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (19) :1998-2006

[4] Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis [J].

Lee, Chee Khoon ;

Brown, Chris ;

Gralla, Richard J. ;

Hirsh, Vera ;

Thongprasert, Sumitra ;

Tsai, Chun-Ming ;

Tan, Eng Huat ;

Ho, James Chung-Man ;

Chu, Da Tong ;

Zaatar, Adel ;

Osorio Sanchez, Jemela Anne ;

Vu Van Vu ;

Au, Joseph Siu Kie ;

Inoue, Akira ;

Lee, Siow Ming ;

Gebski, Val ;

Yang, James Chih-Hsin .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (09) :595-605

[5] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models [J].

Li, D. ;

Ambrogio, L. ;

Shimamura, T. ;

Kubo, S. ;

Takahashi, M. ;

Chirieac, L. R. ;

Padera, R. F. ;

Shapiro, G. I. ;

Baum, A. ;

Himmelsbach, F. ;

Rettig, W. J. ;

Meyerson, M. ;

Solca, F. ;

Greulich, H. ;

Wong, K-K .

ONCOGENE, 2008, 27 (34) :4702-4711

[6] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[7] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Tsurutani, Junji ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

LANCET ONCOLOGY, 2010, 11 (02) :121-128

[8] Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial [J].

Oizumi, Satoshi ;

Kobayashi, Kunihiko ;

Inoue, Akira ;

Maemondo, Makoto ;

Sugawara, Shunichi ;

Yoshizawa, Hirohisa ;

Isobe, Hiroshi ;

Harada, Masao ;

Kinoshita, Ichiro ;

Okinaga, Shoji ;

Kato, Terufumi ;

Harada, Toshiyuki ;

Gemma, Akihiko ;

Saijo, Yasuo ;

Yokomizo, Yuki ;

Morita, Satoshi ;

Hagiwara, Koichi ;

Nukiwa, Toshihiro .

ONCOLOGIST, 2012, 17 (06) :863-870

[9] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [J].

Paz-Ares, L. ;

Tan, E. -H. ;

O'Byrne, K. ;

Zhang, L. ;

Hirsh, V. ;

Boyer, M. ;

Yang, J. C. -H. ;

Mok, T. ;

Lee, K. H. ;

Lu, S. ;

Shi, Y. ;

Lee, D. H. ;

Laskin, J. ;

Kim, D. -W. ;

Laurie, S. A. ;

Kolbeck, K. ;

Fan, J. ;

Dodd, N. ;

Marten, A. ;

Park, K. .

ANNALS OF ONCOLOGY, 2017, 28 (02) :270-277

[10] First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases [J].

Schuler, Martin ;

Wu, Yi-Long ;

Hirsh, Vera ;

O'Byrne, Kenneth ;

Yamamoto, Nobuyuki ;

Mok, Tony ;

Popat, Sanjay ;

Sequist, Lecia V. ;

Massey, Dan ;

Zazulina, Victoria ;

Yang, James C. -H. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) :380-390

← 1 2 →